rejuvant life tabs

Mouse studies and safety to accelerate longevity drugs

Latest articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...
Rejuvant

Professor Mikhail Blagosklonny takes a look at therapeutic research done within the longevity field and concludes that there must be a re-focusing on lifespan extension.

Advancements in modern medicine and a focus on lifespan and healthspan medicine mean that people are living longer. Centenarians – people who live to be over 100 – are no longer uncommon, but could clinical trials for longevity be shorted when using repurposed drugs? One key opinion leader doesn’t think so and is advocating change.

Longevity.Technology: Prolonged life is accompanied by increased incidence of aging diseases. Elderly patients often suffer from co-morbidities including Alzheimer’s, cancer and frailty; the next logical step for medicine, therefore, is to make the added years healthier and for policy makers to drive this progress through regulation and funding.

longevity explainer

Longevity research has various hypotheses of just how aging comes to be. For instance, the geroscience hypothesis focuses on treating age-related diseases, such as cancer, by slowing down aging. However, one of the underlying flaws is that it assumes that aging must be caused by molecular damage that can be treated.

Indeed, many studies focus on anti-oxidant levels, telomere length and other hallmarks of aging; but mortality often occurs before those markers reach a critical and lethal level. This puts into question: is data for lifespan from non-lethal markers valid?

Hyperfunction theory of aging on the other hand puts “aging as a sum of all the age-related diseases and not their risk factors”. It also states that aging occurs due to overactivation, thus hyperfunction, of signalling pathways. Professor Mikhail Blagosklonny, of the Roswell Park Cancer Institute, Buffalo argues for hyperfunction theory in his recent research perspective The goal of geroscience is life extension, writing that “aging and diseases are two sides of the same coin: diseases are manifestations of aging [1].” The goal of geroscience, writes Professor Blagosklonny, is the extension of lifespan by extending healthspan.

 


 

In reviewing FDA-approved drugs on the market (utilised in longevity research) Professor Blagosklonny came to the conclusion that, more often than not, the outcome of these preliminary trials does increase healthspan but decreases lifespan, thus ‘compressing’ the diseased aging period.

 


 

Professor Blagosklonny’s approach would, he argues, “make the current generation of adults live longer and healthier, without conducting lifelong randomized clinical trials.” Professor Blagosklonny explains: “Even if such trials would be started, only the next generation may benefit. But such clinical trials are not needed anymore. For practical purposes, it is both necessary and sufficient that a drug consistently and significantly extend lifespan in mice (and other mammals, if tested) and be already approved for any indication in humans. Given that no proof of life extension in humans (and other long-lived mammals) can be available in our lifetime, we need strong evidence in rodents.”

He outlines one drug that is consistent in prolonging healthspan and lifespan across the literature in various murine models – rapamycin. This drug is normally used as an immunosuppressant in transplant patients. One of the proposed mechanistic pathways for aging according to hyperfunction theory is the mTOR pathway and rapamycin has coincidentally this specific target.

Elevant

Indeed, there has recent focus on rapamycin as an anti-aging treatment; AgelessRx are conducting a Participatory Evaluation of Aging with Rapamycin for longevity (PEARL) trial. It’s a large-scale trial that will give volunteers rapamycin supplements and monitor them, which is the first intervention trial for longevity [2].

 


 

He believes that if drugs have been deemed safe by the FDA and equivalent health and safety organisations, then there is nothing preventing their prescription as supplements.

 


 

 

The Coronavirus has focused the world on the need for compressed trials in certain circumstances; longevity leaders have recently called for trials of rapamycin to treat COVID-19 to get underway as soon as possible, and Oxford’s Professor Lynne Cox wrote in The Lancet advocating for the imminent initiation of trials of potential geroprotective therapies.

Professor Blagosklonny argues that these kinds of trials are key for longevity as conducting conventional human trials and monitoring people throughout their lives is not a realistic goal. He believes that if drugs have been deemed safe by the FDA and equivalent health and safety organisations, then there is nothing preventing their prescription as supplements.

It seems logical that if rapamycin has shown healthspan and lifespan benefit in mice, and it is safe for human consumption with a known mechanistic target mTOR, then it would be safe and might well have the same beneficial effect in humans. As Professor Blagosklonny puts it: “We have one life to live and cannot wait for results in others, if we want to live longer ourselves.”

Elevant

[1] https://www.oncotarget.com/article/27882
[2] https://www.agelessrx.com/how-we-work

 

 

Comment on this article

Victoria Barros Metlova
Staff Writer Victoria is a DPhil candidate in Inorganic Chemistry working on biocatalysis of drug fragments with P450 monooxygenase mutants under the supervision of Professor Luet Wong, at Oxford. She researches and writes about longevity (when her dogs allow her the time!)
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

New perspective in gerontology: epigenetic rejuvenation

Can biological age be set back by "making the clock tick backwards"? Scientists suggest that a partial phenotypic rejuvenation can be gained. Since the discovery...

BioAge licenses Amgen drug to treat muscle aging

Exclusive deal to develop and commercialise Amgen’s Phase 1 APJ agonist, after BioAge platform identifies its potential in promoting longevity and reducing symptoms of...

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...
Supps report ad middle